Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid.

Trial Profile

Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HIV infections
  • Focus Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 06 Apr 2011 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.
    • 09 Aug 2010 Planned end date changed from Aug 2009 to Aug 2011 as reported by ClinicalTrials.gov.
    • 21 May 2009 New source identified and integrated (Vanderbilt University Medical Center Clinical Trials Center).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top